Microbot Medical Target of Unusually High Options Trading (NASDAQ:MBOT)

Microbot Medical Inc. (NASDAQ:MBOT) saw unusually large options trading on Monday. Stock investors acquired 2,704 call options on the stock. This is an increase of 122% compared to the average volume of 1,216 call options.

Microbot Medical Stock Down 16.5%

MBOT traded down $0.47 during trading hours on Monday, reaching $2.35. 3,871,718 shares of the company’s stock traded hands, compared to its average volume of 1,709,578. The firm has a 50-day moving average price of $2.36 and a 200 day moving average price of $1.82. The firm has a market capitalization of $85.31 million, a PE ratio of -2.92 and a beta of 1.14. Microbot Medical has a 52-week low of $0.82 and a 52-week high of $3.38.

Microbot Medical (NASDAQ:MBOT) last released its quarterly earnings data on Wednesday, May 21st. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.07. Equities analysts predict that Microbot Medical will post -0.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Microbot Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in MBOT. Geode Capital Management LLC lifted its stake in Microbot Medical by 7.9% in the fourth quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company’s stock worth $160,000 after acquiring an additional 10,442 shares during the period. Renaissance Technologies LLC purchased a new position in Microbot Medical during the fourth quarter valued at approximately $118,000. Virtu Financial LLC purchased a new stake in Microbot Medical during the first quarter worth $42,000. Finally, Goldman Sachs Group Inc. bought a new stake in Microbot Medical during the 1st quarter valued at $57,000. Institutional investors own 16.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Microbot Medical in a research report on Thursday, April 10th.

Microbot Medical Company Profile

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.